NEW SECONDARY METABOLITES OF PHENYLBUTYRATE IN HUMANS AND RATS

Authors:
  • LBLaura L. Brunengraber
    Laura L. Brunengraber
  • BCBlandine Comte
    Blandine Comte
  • MPMichelle A. Puchowicz
    Michelle A. Puchowicz
  • KJKathryn Jobbins
    Kathryn Jobbins
  • KTKatherine Thomas
    Katherine Thomas
  • FDFrance David
    France David
  • RKRenee Kinman
    Renee Kinman
  • SWSuzanne Wehrli
    Suzanne Wehrli
  • WDWilliam Dahms
    William Dahms
  • DKDouglas Kerr
    Douglas Kerr
  • INItzhak Nissim
    Itzhak Nissim

Abstract
Phenylbutyrate is used to treat inborn errors of ureagenesis, malignancies, cystic fibrosis, and thalassemia. High-dose phenylbutyrate therapy results in toxicity, the mechanism of which is unexplained. The known metabolites of phenylbutyrate are phenylacetate, phenylacetylglutamine, and phenylbutyrylglutamine. These are excreted in urine, accounting for a variable fraction of the dose. We identified new metabolites of phenylbutyrate in urine of normal humans and in perfused rat livers. These metabolites result from interference between the metabolism of phenylbutyrate and that of carbohydrates and lipids. The new metabolites fall into two categories, glucuronides and phenylbutyrate β-oxidation side products. Two questions are raised by these data. First, is the nitrogen-excreting potential of phenylbutyrate diminished by ingestion of carbohydrates or lipids? Second, does competition between the metabolism of phenylbutyrate, carbohydrates, and lipids alter the profile of phenylbutyrate metabolites? Finally, we synthesized glycerol esters of phenylbutyrate. These are partially bioavailable in rats and could be used to administer large doses of phenylbutyrate in a sodium-free, noncaustic form.

This publication has 27 references indexed in Scilit: